SNGX : Summary for Soligenix, Inc. - Yahoo Finance

U.S. Markets open in 2 hrs 2 mins

Soligenix, Inc. (SNGX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.45+0.09 (+3.81%)
At close: 4:00PM EDT
People also watch
FCSCSYNTPIVOGENAPHB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.36
Open2.47
Bid1.68 x 200
Ask0.00 x
Day's Range2.28 - 2.47
52 Week Range1.90 - 9.00
Volume33,674
Avg. Volume82,232
Market Cap18.52M
Beta0.19
PE Ratio (TTM)-1.26
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results

    PRINCETON, N.J., March 27, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2016. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We are extremely pleased with the positive results from the Phase 2 study of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer.

  • PR Newswire13 days ago

    Soligenix to Present Data on Dusquetide in Combating Antibiotic-Resistant Infections at the 19th Annual Superbugs & Superdrugs Conference

    PRINCETON, N.J., March 15, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer of Soligenix will present preclinical and clinical results on the use of dusquetide (SGX94) in the treatment of emerging and antibiotic resistant infectious diseases at Superbugs & Superdrugs – A Focus on Antibacterials.  The conference is being held in London March 20-21, 2017. Innate Defense Regulators: Agnostic Therapy For Antibiotic Resistant Disease – "Supercharging existing and new antibiotic therapies," presented by Dr. Oreola Donini, Chief Scientific Officer of Soligenix, on March 20, 2017 at 1:20 pm local time.  Conference details are available here.

  • Zacks Small Cap Research15 days ago

    Soligenix (SNGX): A Key Player in the Biodefense Space

    On March 10, 2017, Soligenix (SNGX) announced that it will present results from its ricin toxin vaccine (RiVax™) development program on March 15 at the Society of Toxicology 56th Annual Meeting. The poster is titled: Verification of Lethal Doses of Inhaled Ricin in Rhesus Macaques to Support Vaccine Development. RiVax™ is the Company's proprietary vaccine candidate for the prevention of exposure to ricin toxin that utilizes a unique antigen that is completely devoid of the toxic activity of ricin.